Atara Biotherapeutics Inc
ATRA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$125.83M
Close$
$-2.33
127.8% downside
Current Fair Value
127.8% downsideOvervalued by 127.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $125.83 Million |
|---|---|
| Enterprise Value | $133.26 Million |
| Earnings per Share | $2.61 |
| Beta | 0.09 |
| Outstanding Shares | 15,033,000 |
Return
| Return on Equity | 45.11% |
|---|---|
| Return on Assets | -79.38% |
| Return on Invested Capital | -107.89% |
Valuation & Multiples
| P/E Ratio | -6.79 |
|---|---|
| PEG | 2.24 |
| Price to Sales | - |
| Price to Book Ratio | -2.79 |
| Enterprise Value to Revenue | 48.62 |
| Enterprise Value to EBIT | -8.71 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | -0.29 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 29, 2026
EPS Estimate
$-0.28
Consensus analyst estimateRevenue Estimate
$750,000
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 2000% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 29.72% |
|---|---|
| Total Invested | $2,261▼ 100.00% |
| Investors Holding | 2▼ 34.00% |
About Atara Biotherapeutics Inc
14 employees
CEO: Pascal Touchon
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseas...